 現在就能決定患者未來—新診斷糖尿病患控糖治療的黃金組合 | |
| 主辦單位 | 社團法人高雄縣醫師公會 |
| 協辦廠商 | 台灣諾華股份有限公司 |
| 上課日期時間 | 111年9月16日（星期五）12:30~14:30 |
| 課程地點 | 會議網址： |
| 報名截止日期 | 視訊課程免報名 |
| 講師 | 高玉禧 義大醫療財團法人義大醫院內科部新陳代謝科、營養治療科主任 |
| 課程大綱 | There is debate about the optimum early pharmacological treatment of diabetes, although most authorities recommend metformin. Beyond metformin it is usual to add a second therapy, but often this intensification occurs late, long after good glycaemic control is lost 2. Second line agents include dipeptidyl peptidase?4 (DPP?4) inhibitors, which are good candidates for early combination therapy. DPP?4 inhibitors improve glucose homeostasis synergistically with metformin even in mild hyperglycaemia, without the adverse effects of weight gain and hypoglycaemia. VERIFY (Vildagliptin Efficacy in combination with metfoRmIn For earlY treatment of Type 2 diabetes) is an ongoing, 5?year, multinational, multi?ethnic study being conducted in 254 centres across 34 countries (Appendix: Table A1). We aimed to investigate, for the first time, the long?term benefits of early treatment intensification with a DPP?4 inhibitor (vildagliptin)?metformin combination over standard?of?care metformin monotherapy in maintaining durable glycaemic control in people with newly diagnosed Type 2 diabetes. |
| 積分 | 西醫師繼續教育積分、家醫科、內科 |